Norprolac (Quinagolide)

Quinagolide, the active ingredient in Norprolac, is a selective dopamine D2‑receptor agonist presented as an oral tablet. It is used to lower elevated prolactin levels, helping manage hyperprolactinemia, prolactin‑secreting pituitary adenomas (prolactinomas), and to suppress lactation when medically indicated, primarily in adult patients.

GNH USA supplies Norprolac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, including both private and public health systems, and supporting timely delivery to meet clinical demand.

Quinagolide acts on the dopaminergic pathway to control excess prolactin production. - Hyperprolactinemia: reduces serum prolactin concentrations, helping to resolve galactorrhea, restore normal menstrual cycles, and improve fertility. - Prolactinoma: lowers prolactin output from pituitary adenomas, aiding in tumor size control and alleviation of associated visual or endocrine disturbances. - Inhibition of lactation: suppresses milk synthesis and secretion, useful in conditions where lactation must be stopped for medical reasons.

Quinagolide may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset that often resolves with continued therapy. - Headache: transient tension‑type headaches reported by some patients. - Dizziness: occasional light‑headedness, especially when standing quickly. - Fatigue: general tiredness that may improve over time.

Serious or Rare Side Effects: - Valvular heart disease: potential fibrosis of cardiac valves requiring periodic echocardiographic monitoring. - Psychosis: emergence of hallucinations or delusional thoughts, particularly in predisposed individuals. - Severe hypotension: marked drop in blood pressure that can cause fainting or shock.

When prescribing Quinagolide, clinicians should consider several safety aspects. - Renal impairment: adjust monitoring as quinagolide is excreted renally. - Cardiovascular disease: evaluate for valvular heart disease before initiating therapy. - Psychiatric disorders: monitor for emergence of psychotic symptoms during treatment. - Pregnancy and lactation: use only if benefits outweigh risks, as safety is unknown. - Drug interactions: review concomitant medications that affect dopamine pathways. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Quinagolide can interact with other medicines; awareness of the interaction level helps guide clinical decisions.

Major Interactions (Avoid): - Antipsychotics (e.g., haloperidol): may antagonize dopamine agonist effect, reducing efficacy. - Ergot derivatives: combined use increases risk of vasospasm and peripheral ischemia. - MAO inhibitors: potential for hypertensive crisis when used together.

Moderate Interactions (Monitor Closely): - Antihypertensives: additive blood‑pressure‑lowering effect may require dose adjustment. - SSRIs: may increase the incidence of nausea and dizziness. - CYP450 inhibitors/inducers: can alter quinagolide plasma concentrations, necessitating therapeutic monitoring.